A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Cancer Research

• Publication date

  2012-11-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-1201PMID 23136196PMCID PMC4104496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

  2013cited by this paper
• Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of Irinotecan, in patients with pre-treated metastatic breast cancer (MBC)

  2010cited by this paper
• Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme

  2010cited by this paper
• Fcgamma receptor polymorphisms as biomarkers for epidermal growth factor receptor antibodies.

  2010cited by this paper
• Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

  2010cited by this paper
• Polyethylene glycol conjugation of irinotecan improves its antitumor activity in three mouse xenograft models

  2007cited by this paper
• Topoisomerase I inhibitors: camptothecins and beyond

  2006influential reference
• Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.

  2004cited by this paper
• Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

  2004cited by this paper
• Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.

  2004cited by this paper
• Irinotecan (Campto®) in the treatment of pancreatic cancer

  2003cited by this paper
• Understanding and managing chemotherapy-induced diarrhea.

  2003cited by this paper
• Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.

  2002cited by this paper
• Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

  2002cited by this paper
• Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.

  2001cited by this paper
• World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects Revised October 7, 2000

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma

  1999cited by this paper
• CPT-11 in gastrointestinal cancer.

  1999cited by this paper
• Topoisomerase I inhibitors: review and update.

  1997cited by this paper
• Accelerated titration designs for phase I clinical trials in oncology.

  1997cited by this paper
• Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.

  1996cited by this paper
• Future directions for clinical research with CPT-11 (irinotecan).

  1996cited by this paper
• CPT-11: an original spectrum of clinical activity.

  1996cited by this paper
• Future directions for clinical research with CPT-11 (irinotecan).

  1996cited by this paper
• Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

  1995cited by this paper
• Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.

  1994cited by this paper
• Bowel rest, intravenous hydration, and continuous high‐dose infusion of octreotide acetate for the treatment of chemotherapy‐induced diarrhea in patients with colorectal carcinoma

  1993cited by this paper
• Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.

  1992cited by this paper
• [Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].

  1990cited by this paper

• Etirinotecan Pegol (NKTR‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer

  2025cites this paper
• Research Progress of Conjugated Nanomedicine for Cancer Treatment

  2022cites this paper
• Nanocarriers Call the Last Shot in the Treatment of Brain Cancers

  2022cites this paper
• Highway to Success—Developing Advanced Polymer Therapeutics

  2021cites this paper
• Recent applications and strategies in nanotechnology for lung diseases

  2021cites this paper
• Clinical Applications of Nanomedicines in Lung Cancer Treatment.

  2020cites this paper
• Camptothecin: chemistry, biosynthesis, analogs, and chemical synthesis

  2020cites this paper
• Emerging PEGylated non-biologic drugs

  2019cites this paper
• Current Diagnosis and Management of Small-Cell Lung Cancer.

  2019cites this paper
• Personalized medicine in breast cancer: pharmacogenomics approaches

  2019cites this paper
• Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer

  2019influential citation
• Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft

  2019cites this paper
• The State of the Art of Investigational and Approved Nanomedicine Products for Nucleic Acid Delivery

  2019cites this paper
• Advances in Delivery of Irinotecan (CPT-11) Active Metabolite 7-Ethyl-10-Hydroxycamptothecin.

  2019cites this paper
• Personalized medicine in breast cancer: pharmacogenomics approaches

  2019cites this paper
• Nanotechnology in the diagnosis and treatment of lung cancer.

  2019cites this paper
• ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

  2019cites this paper
• PGPM_A_167886 59..73

  2019cites this paper
• Clinical developments of antitumor polymer therapeutics

  2019cites this paper
• Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives

  2018cites this paper
• Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

  2018cites this paper
• Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors

  2018cites this paper
• Camptothecin induces G 2 / M phase arrest through the ATM-Chk 2-Cdc 25 C axis as a result of autophagy-induced cytoprotection : Implications of reactive oxygen species

  2018cites this paper
• Camptothecin induces G2/M phase arrest through the ATM-Chk2-Cdc25C axis as a result of autophagy-induced cytoprotection: Implications of reactive oxygen species

  2018cites this paper
• Polymer–drug conjugate therapeutics: advances, insights and prospects

  2018cites this paper
• Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.

  2017cites this paper
• Etirinotecan Pegol (NKTR‐102) in Third‐line Treatment of Patients With Metastatic or Recurrent Non–Small‐cell Lung Cancer: Results of a Phase II Study

  2017cites this paper
• Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer

  2017cites this paper
• A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.

  2017cites this paper
• Tumour regression and improved gastrointestinal tolerability from controlled release of SN‐38 from novel polyoxazoline‐modified dendrimers

  2017cites this paper
• Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

  2016cites this paper
• Etirinotecan pegol for the treatment of breast cancer

  2016cites this paper
• Chemotherapy principles of managing stage IV breast cancer in the United States.

  2016cites this paper
• Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration

  2016cites this paper
• Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.

  2016cites this paper
• PEGylation in anti-cancer therapy: An overview

  2016cites this paper
• Current controversies in the management of metastatic colorectal cancer

  2015cites this paper
• Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.

  2015cites this paper
• Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report

  2015influential citation
• Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma

  2015cites this paper
• NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer

  2015cites this paper
• Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

  2015cites this paper
• Camptothecin-Discovery, Clinical Perspectives and Biotechnology

  2015cites this paper
• Lamellarins: A Tribe of Bioactive Marine Natural Products

  2014cites this paper
• Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models

  2014cites this paper
• Etirinotecan Pegol: Development of a Novel Conjugated Topoisomerase I Inhibitor

  2014cites this paper
• Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

  2013cites this paper
• Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

  2013cites this paper
• Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development

  2013cites this paper
• A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

  2013cites this paper